A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells

Immune tolerance to tumor-associated carbohydrate antigens (TACAs) has severely restricted the usefulness of most TACAs. To overcome this problem, we selected a sialylated trisaccharide TACA, GM3, as a target antigen, and tested a new immunotherapeutic strategy by combining metabolic bioengineering...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Lei, Li, Jie, Yu, Shichong, Wang, Qianli, Li, Yinghua, Hu, Zhenlin, Wu, Qiuye, Guo, Zhongwu, Zhang, Junping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467142/
https://www.ncbi.nlm.nih.gov/pubmed/25760071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467142/
https://www.ncbi.nlm.nih.gov/pubmed/25760071

Ejemplares similares